Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have identified three Russell 2000 companies with strong fundamentals and growth potential, each offering more than 80% upside from current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Let’s dive into the details. Click on any ticker to explore each stock further and decide if it deserves a spot in your portfolio.
Beam Therapeutics (BEAM)
Beam Therapeutics is a biotechnology company focused on precision genetic medicines. Year-to-date, BEAM stock has declined by over 24%.
Looking ahead, Wall Street remains strongly bullish on BEAM stock. Overall, 12 out of 14 analysts rate BEAM stock as a Buy. The average Beam Therapeutics’ stock price target of $42.67 implies a potential upside of 128% from current levels.
Benitec Biopharma (BNTC)
Benitec Biopharma is a biotechnology company developing a unique therapeutic platform that combines RNA interference (RNAi) with gene therapy to treat genetic diseases. BNTC stock has gained 10% so far in 2025.
According to TipRanks, BNTC stock has unanimous Buy recommendations from all three analysts covering it. Benitec’s average stock price target of $25.00 suggests a potential upside of 80% from current levels.
Apogee Therapeutics (APGE)
Apogee Therapeutics is a clinical-stage biotech company focused on developing novel biologic therapies for inflammatory and immunological diseases. Year-to-date, APGE stock has declined by almost 15%.
Overall, APGE stock has unanimous Buy recommendations from all nine analysts covering it. Apogee’s average stock price target of $97.88 suggests a potential upside of 155% from current levels.
